$GMAB mention timeline

Genmab A/S. Every tracked FinTwit mention of $GMAB, newest first. 24 mentions since the first on Jul 9, 2025. See the price chart.

February 2026 · 3 mentions

Feb 23
Jacob Plieth — Why is $BCAX testing a ficera dose in phase 3 that it now says isn't optimal (and other uncomfortable questions)? Via @ApexOnco -> https://t.co/mLWKP6AAZ9 $JNJ $GMAB↗
Feb 23
Jacob Plieth — @robertcoffin3 What about $MRUS $GMAB claim to be active in HPV+ves?↗
Feb 9
Jacob Plieth — Interesting disclosure from $ABBV Q4 presentation: ABBV-901 is an anti-FRα ADC - so trying to improve on Elahere given the threats of $GMAB $LLY etc? https://t.co/X1RDASBmcp↗

Jan 29
Jacob Plieth — With a tipoff from a friend, and some info that probably shouldn't have been posted in a trial registry, the mechanisms of ADCs JNJ-95437446 $JNJ & SKB571/ MK-2750 $MRK have be…↗
Jan 22
Jacob Plieth — @EgidiusLambrech ...though I wouldn't be holding out too much hope for MCLA-129, given the stinking data it's produced so far on the tox side. Expect $GMAB to drop that one imminen…↗

Dec 30
Jacob Plieth — Beautifully buried discontinuation of acasunlimab by $GMAB yesterday. A disaster that's been a long time coming, and remember GMAB went into phase 3 on its own despite $BNTX earlie…↗

Nov 19
Jacob Plieth — $GMAB $ABBV Epkinly approval for 2L follicular effectively scoops the upcoming #ASH25 data presentation https://t.co/3Wk2srPEs4↗
Nov 17
Jacob Plieth — Looks like $GMAB just discontinued GEN1160 (Profoundbio's anti-CD70 ADC). https://t.co/S4XWQGpsiZ↗
Nov 14
Jacob Plieth — Here's $STRO first dual-payload ADC project, STRO-227. PTK7 seems like a risky target given $GMAB $PFE $ABBV experience https://t.co/nCERSesrPs↗
Nov 13
Jacob Plieth — @jfais20 Absolutely fair point; $DAWN is skating on thin ice in PTK7 since $GMAB $PFE $ABBV have all failed.

Oct 22
Jacob Plieth — Who won #ESMO25 and who lost? Via @ApexOnco https://t.co/EWzHIIH1Ck $IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $Z…↗
Oct 20
Jacob Plieth — Good morning biotwitter! If you're catching up with #ESMO25 here's what we've published over the weekend https://t.co/lzhy6k4Raz Stocks to watch this morning: $GMAB $CELC $IOBT $MR…↗
Oct 20
Jacob Plieth — $GMAB off 4% premarket #ESMO25 https://t.co/iOHfipgRHL↗
Oct 20
Jacob Plieth — From #ESMO25 yesterday, via @ApexOnco -> how $LLY sprang a surprise for $AZN in FRα. Also key datasets for $GMAB https://t.co/UfWdYMuyKe

Sep 29
Jacob Plieth — Petosemtamab delivers a buyout for $MRUS. @ApexOnco take on the $8bn acquisition by $GMAB https://t.co/KqNb9vt7pI $BCAX↗
Sep 29
Jacob Plieth — @bradloncar $MRUS #ASCO25 data were a major validation, but this is still a high-risk bet on ph3. I guess some time next year we find out whether this is $GMAB $8bn well spent.↗
Sep 29
Jacob Plieth — 43 patients' worth of data = $8bn, of which $5.5bn is being financed through debt $MRUS $GMAB↗
Sep 29
Adam Feuerstein ✡️ — Good Monday morning! Genmab $GMAB to buy Merus $MRUS in $8B deal https://t.co/DpzzMvM4Hi via @DrewQJoseph

Aug 7
Jacob Plieth — As if $REGN TCE division needed any more bad news, $GMAB Epcore FL-1 just read out positively, about 3 years ahead of schedule as far as I can tell.↗

Jul 9
Jacob Plieth — $GMAB quietly discontinued the mystery oncology project GEN1078, months after it first went into phase 1. Likely T-cell engager via Omniab; any idea as to target(s)? Via @ByMadelei…↗